| Literature DB >> 30819078 |
Eva Mezeiova1,2,3, Katarina Chalupova1,2,4, Eugenie Nepovimova4, Lukas Gorecki1,3, Lukas Prchal1, David Malinak1,4, Kamil Kuca1,4, Ondrej Soukup1,2,3, Jan Korabecny1,2,3.
Abstract
Alzheimer's Disease (AD) is a neurodegenerative disorder with an increasing impact on society. Because currently available therapy has only a short-term effect, a huge number of novel compounds are developed every year exploiting knowledge of the various aspects of AD pathophysiology. To better address the pathological complexity of AD, one of the most extensively pursued strategies by medicinal chemists is based on Multi-target-directed Ligands (MTDLs). Donepezil is one of the currently approved drugs for AD therapy acting as an acetylcholinesterase inhibitor. In this review, we have made an extensive literature survey focusing on donepezil-derived MTDL hybrids primarily targeting on different levels cholinesterases and amyloid beta (Aβ) peptide. The targeting includes direct interaction of the compounds with Aβ, AChE-induced Aβ aggregation, inhibition of BACE-1 enzyme, and modulation of biometal balance thus impeding Aβ assembly. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Acetylcholinesterase; Alzheimer`s disease; amyloid-β; beta-secretase 1; biometal; butyrylcholinesterase; multitargetzzm321990directed ligands; neuroprotection.
Year: 2019 PMID: 30819078 DOI: 10.2174/1567205016666190228122956
Source DB: PubMed Journal: Curr Alzheimer Res ISSN: 1567-2050 Impact factor: 3.498